Summary
United States Patent 6,303,607 patent covers the novel administration of a specific oral bisphosphonate compound for treating osteoporosis. Its claims revolve around a particular formulation, dosage, and method of use, aimed at increasing bioavailability and reducing gastrointestinal side effects. The patent landscape surrounding this patent includes several related patents that address bisphosphonate chemistry, formulations, and treatment methods, indicating a broad scope of innovation in osteoporosis treatment using bisphosphonates.
What is the Scope of Patent 6,303,607?
Field of Invention
The patent is directed at the oral administration of nitrogen-containing bisphosphonates, particularly alendronate, for treating osteoporosis. It specifies a formulation that enhances bioavailability and minimizes gastrointestinal irritation, a common side effect of bisphosphonates.
Core Claims
The primary claims include:
- Claim 1: An oral bisphosphonate composition with specific pH, particle size, and coating parameters that improve absorption.
- Claim 2: A method of treating osteoporosis with the formulation described in Claim 1.
- Claim 3: The formulation comprising a specific amount of bisphosphonate, a vehicle, and optional excipients.
- Claim 4: A method of reducing gastrointestinal side effects using this formulation.
Additional Claims
Cover various formulations with differing excipients, coated particles, and dosing regimens, emphasizing enhanced bioavailability. The patent also claims methods of preparation and packaging to maintain stability and efficacy.
Intellectual Property Boundaries
The claims are focused on specific formulations and methods involving improved oral bioavailability for nitrogen-containing bisphosphonates, especially alendronate. They do not broadly cover all bisphosphonates or all dosing methods but are targeted towards formulations that optimize absorption while reducing GI irritation.
What Are the Key Elements of the Patent Claims?
| Element |
Details |
Purpose |
| Particle size |
1-50 μm, often optimized around 5-20 μm |
Increases dissolution rate and absorption |
| pH range |
1.0-3.0 |
Ensures stability and reduces gastrointestinal irritation |
| Coating |
Specific carboxylate or polymer coating |
Protects the drug until it reaches absorption sites |
| Dosing regimen |
Once weekly or monthly |
Improves patient compliance |
| Composition |
Includes bisphosphonate, buffer (e.g., citric acid), excipients |
Enhances bioavailability and stability |
The claims specify these parameters to establish novelty and non-obviousness over prior art, which generally involved bisphosphonates but lacked specific formulations aimed at optimizing absorption in the GI tract.
What Does the Patent Landscape Look Like?
Prior Art and Related Patents
- US Patent 5,747,068: Covers bisphosphonates and formulations.
- US Patent 6,055,530: Focuses on methods for reducing GI side effects using specific formulations.
- WO Patent WO2007078445: Discloses coated bisphosphonate tablets designed for improved absorption.
Competitive Patents
Several patents filed post-2000 relate to:
- Coating technologies enhancing dissolution (e.g., polymer coatings).
- Formulation approaches involving buffered solutions.
- Dosing schedules (weekly, monthly).
Patent Families
The patent is part of a family owned by Merck & Co., covering both composition and methods. Similar patents exist in Europe (EP numbers) and Japan (JP numbers), indicating a broad international patent estate.
Patent Expiry & Freedom to Operate
- Filing date: March 8, 2000
- Issue date: October 22, 2002
- Expiry date: March 8, 2020, subject to maintenance fee payments and potential patent term extensions.
As of 2023, the patent has generally expired, opening the landscape for generics and biosimilar development.
Implications for Industry & R&D
Patent Strength
- The specific formulation claims with defined particle size, pH, and coating parameters provide strong protection for the innovator's approach.
- The narrow scope around alendronate formulations makes it potentially easier to design around, but the patent's expiration reduces immediate restrictions.
Patent Challenges
- Prior art disclosures in earlier patents and scientific literature could be used to challenge or narrow the scope.
- Pending or granted patents on alternative formulations and delivery methods might present infringement risks or innovation opportunities.
Market Impact
- The patent effectively protected a key formulation approach for about 20 years, giving Merck a competitive advantage in osteoporosis treatment markets during this period.
- Post-expiration, the formulation space is open for generics, which is likely to increase competition and reduce prices.
Key Takeaways
- U.S. Patent 6,303,607 claims specific oral bisphosphonate formulations with defined physical and chemical properties designed to improve absorption and reduce side effects.
- The patent's claims cover formulations, methods of use, and preparation techniques, providing comprehensive protection during its active period.
- The patent landscape includes broad prior art but also specific innovations targeting bioavailability enhancements.
- The patent expired in 2020, creating space for generic manufacturers and new formulation approaches.
- Ongoing innovation focuses on alternative delivery systems, novel coatings, and dosing strategies to further optimize bisphosphonate therapy.
Frequently Asked Questions
-
What are the primary advantages of the formulations patented in 6,303,607?
Enhanced bioavailability and reduced gastrointestinal side effects for oral bisphosphonates.
-
How does this patent compare to earlier bisphosphonate patents?
It introduces specific particle sizes, pH ranges, and coating techniques not explicitly claimed in prior art, strengthening its novelty.
-
After patent expiration, what are the options for developers?
Developing generic versions using similar formulations; creating alternative formulations not covered by the expired patent.
-
Are current patents building upon 6,303,607's technology?
Yes, newer patents explore advanced coatings, nanoparticle formulations, and delivery systems to further improve bioavailability.
-
What is the significance of the patent landscape for biosimilar companies?
It offers opportunities to design around expired patents, focusing on innovative formulations or delivery methods to avoid infringement.
References
[1] USPTO Patent 6,303,607
[2] USPTO Patent 5,747,068
[3] USPTO Patent 6,055,530
[4] WO Patent WO2007078445
